Cynthia Hawkins

List of Publications by Year
in descending order

252 papers	29,576 citations	28190 55 h-index	5364 164 g-index
266 all docs	266 docs citations	266 times ranked	26967 citing authors

#	Article	IF	Citations
1	Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.	13.7	6,758
2	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	0.6	4,534
3	Identification of a cancer stem cell in human brain tumors. Cancer Research, 2003, 63, 5821-8.	0.4	3,675
4	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	3.9	799
5	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	13.5	743
6	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	7.7	716
7	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	13.5	596
8	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 2014, 46, 451-456.	9.4	525
9	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	2.1	499
10	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	15.2	473
11	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
12	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	2.1	363
13	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	5.1	307
14	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nature Genetics, 2015, 47, 257-262.	9.4	306
15	Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor Î± and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets. Journal of Clinical Oncology, 2010, 28, 1337-1344.	0.8	292
16	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathologica, 2014, 128, 573-581.	3.9	258
17	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	0.8	250
18	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	7.7	244

#	Article	IF	Citations
19	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	0.8	232
20	BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma. Clinical Cancer Research, 2011, 17, 4790-4798.	3.2	219
21	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	0.6	217
22	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
23	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncology, The, 2013, 14, 534-542.	5.1	212
24	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	5.8	200
25	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2012, 30, 1358-1363.	0.8	198
26	TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors. Journal of Clinical Oncology, 2010, 28, 1995-2001.	0.8	189
27	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	3.3	188
28	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. European Journal of Cancer, 2014, 50, 987-996.	1.3	180
29	Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathologica Communications, 2020, 8, 30.	2.4	172
30	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 2019, 137, 683-687.	3.9	170
31	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	3.9	168
32	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	2.1	168
33	Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. Journal of Neurosurgery, 2015, 122, 1360-1369.	0.9	166
34	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine, 2016, 8, 366ra161.	5.8	144
35	Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathologica Communications, 2016, 4, 1.	2.4	144
36	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	15.2	141

#	Article	IF	Citations
37	Alkylpurineâ€“DNAâ€“N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Journal of Clinical Investigation, 2012, 122, 253-266.	3.9	140
38	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. Clinical Cancer Research, 2011, 17, 4650-4660.	3.2	135
39	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	3.9	120
40	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	0.6	116
41	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. Neuro-Oncology, 2016, 18, 291-297.	0.6	112
42	Clinical and treatment factors determining longâ€term outcomes for adult survivors of childhood lowâ€grade glioma: A populationâ€based study. Cancer, 2016, 122, 1261-1269.	2.0	109
43	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. Cancer Research, 2016, 76, 4708-4719.	0.4	107
44	Human Telomere Reverse Transcriptase Expression Predicts Progression and Survival in Pediatric Intracranial Ependymoma. Journal of Clinical Oncology, 2006, 24, 1522-1528.	0.8	106
45	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathologica Communications, 2016, 4, 93.	2.4	100
46	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2015, 5, 147.	1.3	91
47	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. European Journal of Cancer, 2015, 51, 977-983.	1.3	87
48	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
49	A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. Journal of Experimental Medicine, 2011, 208, 689-702.	4.2	77
50	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	0.6	73
51	The Role of Telomere Maintenance in the Spontaneous Growth Arrest of Pediatric Low-Grade Gliomas. Neoplasia, 2006, 8, 136-142.	2.3	72
52	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. Journal of Clinical Oncology, 2016, 34, 4161-4170.	0.8	72
53	Lethal Disorder of Mitochondrial Fission Caused by Mutations in DNM1L. Journal of Pediatrics, 2016, 171, 313-316.e2.	0.9	67
54	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	3.9	65

#	Article	IF	Citations
55	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	2.1	63
56	High frequency of mismatch repair deficiency among pediatric high grade gliomas in <scp>J</scp>ordan. International Journal of Cancer, 2016, 138, 380-385.	2.3	62
57	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	1.5	62
58	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1â€deficient nonâ€rhabdoid tumor with favorable longâ€term outcome. Brain Pathology, 2017, 27, 411-418.	2.1	58
59	Profound clinical and radiological response to BRAF inhibition in a 2â€monthâ€old diencephalic child with hypothalamic/chiasmatic glioma. Pediatric Blood and Cancer, 2016, 63, 2038-2041.	0.8	57
60	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. Cancer Cell, 2020, 37, 308-323.e12.	7.7	56
61	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. Cancer Discovery, 2014, 4, 1198-1213.	7.7	55
62	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular Cancer Therapeutics, 2015, 14, 2560-2568.	1.9	55
63	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	15.2	53
64	Tyrosine kinase expression in pediatric high grade astrocytoma. Journal of Neuro-Oncology, 2008, 87, 247-253.	1.4	51
65	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatric Blood and Cancer, 2018, 65, e26988.	0.8	51
66	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. Neuro-Oncology, 2020, 22, 1647-1657.	0.6	51
67	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	2.0	49
68	Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas. Neuro-Oncology, 2020, 22, 139-151.	0.6	49
69	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Child's Nervous System, 2017, 33, 1047-1051.	0.6	46
70	A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. Brain Tumor Pathology, 2017, 34, 51-61.	1.1	46
71	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	0.6	44
72	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	3.9	44

#	Article	IF	Citations
73	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	1.4	43
74	Germline and somatic mutations in STXBP1 with diverse neurodevelopmental phenotypes. Neurology: Genetics, 2017, 3, e199.	0.9	41
75	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clinical Cancer Research, 2015, 21, 3750-3758.	3.2	40
76	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Childrenâ€™s Oncology Group (ACNS1221). Journal of Clinical Oncology, 2020, 38, 223-231.	0.8	40
77	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	0.8	40
78	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	0.8	40
79	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Reports, 2020, 33, 108286.	2.9	39
80	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	0.6	39
81	Pediatric thalamic tumors in the MRI era: a Canadian perspective. Child's Nervous System, 2016, 32, 269-280.	0.6	37
82	Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. Nature Communications, 2020, 11, 6216.	5.8	35
83	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2+ Granule Neuron Precursor. Cell Reports, 2020, 31, 107511.	2.9	35
84	A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. European Journal of Cancer, 2009, 45, 2352-2359.	1.3	34
85	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathologica, 2014, 128, 863-877.	3.9	34
86	B7â€“H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. Translational Oncology, 2020, 13, 365-371.	1.7	33
87	An update on the CNS manifestations of brain tumor polyposis syndromes. Acta Neuropathologica, 2020, 139, 703-715.	3.9	33
88	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro-Oncology, 2019, 21, 547-557.	0.6	32
89	Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of BRAF-Mutated and BRAF-Fused Tumors. American Journal of Neuroradiology, 2021, 42, 759-765.	1.2	32
90	Identification of complex genomic rearrangements in cancers using CouGaR. Genome Research, 2017, 27, 107-117.	2.4	31

#	Article	IF	Citations
91	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Research, 2018, 78, 4745-4759.	0.4	31
92	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	1.4	30
93	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. Journal of Clinical Neuroscience, 2016, 34, 169-176.	0.8	29
94	Diffuse midline glioma: review of epigenetics. Journal of Neuro-Oncology, 2020, 150, 27-34.	1.4	29
95	Rasmussenâ€™s encephalitis: advances in management and patient outcomes. Child's Nervous System, 2016, 32, 629-640.	0.6	27
96	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	1.4	27
97	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. Child's Nervous System, 2016, 32, 1789-1797.	0.6	26
98	Cribriform neuroepithelial tumour: novel clinicopathological, ultrastructural and cytogenetic findings. Acta Neuropathologica, 2011, 122, 511-514.	3.9	24
99	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nature Communications, 2019, 10, 797.	5.8	24
100	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget, 2015, 6, 2709-2724.	0.8	24
101	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. Acta Neuropathologica, 2020, 140, 765-776.	3.9	23
102	Local FK506 drug delivery enhances nerve regeneration through fresh, unprocessed peripheral nerve allografts. Experimental Neurology, 2021, 341, 113680.	2.0	23
103	Massive CAG Repeat Expansion and Somatic Instability in Maternally Transmitted Infantile Spinocerebellar Ataxia Type 7. JAMA Neurology, 2015, 72, 219.	4.5	22
104	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
105	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. Clinical Epigenetics, 2019, 11, 117.	1.8	21
106	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nature Communications, 2020, 11, 3627.	5.8	21
107	GLI2 Is a Potential Therapeutic Target in Pediatric Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2011, 70, 430-437.	0.9	20
108	Loss of p53 cooperates with Kâ€ras activation to induce glioma formation in a regionâ€independent manner. Glia, 2013, 61, 1862-1872.	2.5	19

#	Article	IF	Citations
109	Transcriptional repressor REST drives lineage stageâ€“specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	1.6	19
110	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. Journal of Neuropathology and Experimental Neurology, 2020, 79, 437-447.	0.9	19
111	JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma. Cancer Research, 2016, 76, 2802-2812.	0.4	18
112	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. Journal of Neuro-Oncology, 2019, 145, 107-114.	1.4	18
113	Cancer proteome and metabolite changes linked to SHMT2. PLoS ONE, 2020, 15, e0237981.	1.1	18
114	Medulloblastoma: WHO 2021 and Beyond. Pediatric and Developmental Pathology, 2022, 25, 23-33.	0.5	18
115	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. Journal of Pediatric Hematology/Oncology, 2018, 40, 478-482.	0.3	17
116	Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nature Communications, 2022, 13, 588.	5.8	17
117	Prognostic relevance of miRâ€124â€3p and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes and Cancer, 2017, 56, 639-650.	1.5	16
118	Hemorrhagic presentations of cerebellar pilocytic astrocytomas in children resulting in death: report of 2 cases. Journal of Neurosurgery: Pediatrics, 2016, 17, 446-452.	0.8	15
119	Two different STAT1 gain-of-function mutations lead to diverse IFN-Î³-mediated gene expression. Npj Genomic Medicine, 2018, 3, 23.	1.7	14
120	Repeat irradiation for children with supratentorial highâ€grade glioma. Pediatric Blood and Cancer, 2019, 66, e27881.	0.8	14
121	Differential transformation capacity of neuro-glial progenitors during development. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14378-14383.	3.3	13
122	Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. Child's Nervous System, 2016, 32, 553-557.	0.6	13
123	Viruses and human brain tumors: cytomegalovirus enters the fray. Journal of Clinical Investigation, 2011, 121, 3831-3833.	3.9	13
124	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	2.7	12
125	Sarcoma Subgrouping by Detection of Fusion Transcripts Using NanoString nCounter Technology. Pediatric and Developmental Pathology, 2019, 22, 205-213.	0.5	11
126	MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii110-ii110.	0.6	10

#	Article	IF	Citations
127	Acute MR-Guided High-Intensity Focused Ultrasound Lesion Assessment Using Diffusion-Weighted Imaging and Histological Analysis. Frontiers in Neurology, 2019, 10, 1069.	1.1	10
128	Multiplexed Digital Detection of B-Cell Acute Lymphoblastic Leukemia Fusion Transcripts Using the NanoString nCounter System. Journal of Molecular Diagnostics, 2020, 22, 72-80.	1.2	10
129	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. Child's Nervous System, 2019, 35, 861-864.	0.6	9
130	Characteristics of patients â‰¥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro-Oncology, 2022, 24, 141-152.	0.6	9
131	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro-Oncology, 2022, 24, 821-833.	0.6	9
132	Noncompaction cardiomyopathy in an infant with Walkerâ€“Warburg syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 3082-3086.	0.7	8
133	Embryonal tumor with multilayered rosettes, C19MC-altered: Report of an extremely rare malignant pediatric central nervous system neoplasm. SAGE Open Medical Case Reports, 2017, 5, 2050313X1774520.	0.2	8
134	BRAF V600E mutant oligodendrogliomaâ€like tumors with chromosomal instability in adolescents and young adults. Brain Pathology, 2020, 30, 515-523.	2.1	8
135	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). Journal of Neuro-Oncology, 2020, 149, 45-54.	1.4	8
136	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. JCO Precision Oncology, 2022, 6, e2100286.	1.5	8
137	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Communications Biology, 2022, 5, .	2.0	8
138	Mitochondrial POLG related disorder presenting prenatally with fetal cerebellar growth arrest. Metabolic Brain Disease, 2018, 33, 1369-1373.	1.4	7
139	Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome. European Journal of Medical Genetics, 2019, 62, 103706.	0.7	7
140	Pearls & Oy-sters: Fatal brain edema is a rare complication of severe CACNA1A-related disorder. Neurology, 2020, 94, 631-634.	1.5	7
141	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of ageâ€"A report from the Children Oncology Group.. Journal of Clinical Oncology, 2017, 35, 10505-10505.	0.8	7
142	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 814228.	1.3	7
143	Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 2022, 144, 373-376.	3.9	7
144	A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. Journal of Neuro-Oncology, 2015, 122, 471-480.	1.4	6

#	Article	IF	Citations
145	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. Pediatric Neurology, 2015, 53, 238-242.e1.	1.0	6
146	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. Neuro-Oncology Advances, 2020, 2, vdaa103.	0.4	6
147	MetaFusion: a high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates. Bioinformatics, 2021, 37, 3144-3151.	1.8	6
148	Upfront Adjuvant Immunotherapy of Replication Repairâ€“Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach. JCO Precision Oncology, 2021, 5, 1426-1431.	1.5	6
149	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. Canadian Association of Radiologists Journal, 2023, 74, 119-126.	1.1	6
150	Ependymal Tumors. Pediatric and Developmental Pathology, 2022, 25, 59-67.	0.5	5
151	Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro-Oncology, 2023, 25, 54-67.	0.6	5
152	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	0.6	4
153	Indolent course of brainstem tumors with K27Mâ€H3.3 mutation. Pediatric Blood and Cancer, 2020, 67, e28102.	0.8	4
154	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. Frontiers in Immunology, 2019, 10, 3045.	2.2	4
155	Building the ecosystem for pediatric neuroâ€oncology care in Pakistan: Results of a 7â€year long twinning program between Canada and Pakistan. Pediatric Blood and Cancer, 2022, 69, e29726.	0.8	4
156	Pediatric Glial Tumors. Pediatric and Developmental Pathology, 2021, , 109352662110091.	0.5	3
157	Abstract 636: PROFYLE: The pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-treat cancer. , 2021, , .		3
158	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. Journal of Clinical Oncology, 2016, 34, 10509-10509.	0.8	3
159	MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES. Neuro-Oncology, 2020, 22, iii393-iii394.	0.6	3
160	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e347-e347.	0.8	2
161	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3.	0.6	2
162	MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP. Neuro-Oncology, 2018, 20, i118-i119.	0.6	2

#	Article	IF	Citations
163	IMMU-25. PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) IS NOT EXPRESSED IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TUMOR CELLS. Neuro-Oncology, 2018, 20, vi126-vi126.	0.6	2
164	Detecting Stem Cell Marker Expression Using the NanoString nCounter System. Methods in Molecular Biology, 2019, 1869, 57-67.	0.4	2
165	Giant choroid plexus cysts with calvarial erosion: a case report and literature review. Child's Nervous System, 2021, 37, 2381-2385.	0.6	2
166	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E lowâ€grade glioma. Pediatric Blood and Cancer, 2021, 68, e28561.	0.8	2
167	Reâ€irradiation with concurrent BRAF and MEK inhibitor therapy. Pediatric Blood and Cancer, 2021, 68, e28838.	0.8	2
168	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. Pediatric Blood and Cancer, 2022, 69, e29316.	0.8	2
169	SYST-04. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology Advances, 2021, 3, iv9-iv9.	0.4	2
170	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. Journal of Clinical Oncology, 2013, 31, 10029-10029.	0.8	2
171	OUP accepted manuscript. American Journal of Clinical Pathology, 2022, , .	0.4	2
172	IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors. Neuro-Oncology, 2022, 24, i85-i85.	0.6	2
173	Genetic alterations in paediatric high grade astrocytomas. Diagnostic Histopathology, 2014, 20, 84-90.	0.2	1
174	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. Neuro-Oncology, 2016, 18, iii82.3-iii82.	0.6	1
175	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. Neuro-Oncology, 2018, 20, i117-i117.	0.6	1
176	DIPG-69. CHARACTERISTICS OF PATIENTS â‰¥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	0.6	1
177	Modeling DIPG in the mouse brainstem. Neuro-Oncology, 2020, 22, 307-308.	0.6	1
178	Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. American Journal of Neuroradiology, 2021, 42, 766-773.	1.2	1
179	A Practical Approach to the Evaluation and Diagnosis of Pediatric CNS Tumors. Pediatric and Developmental Pathology, 2022, 25, 6-9.	0.5	1
180	Childhood head trauma and the risk of childhood brain tumours: A caseâ€control study in Ontario, Canada. International Journal of Cancer, 2022, 150, 795-801.	2.3	1

#	Article	IF	Citations
181	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. Neuro-Oncology, 2020, 22, iii363-iii363.	0.6	1
182	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. Neuro-Oncology, 2020, 22, iii407-iii407.	0.6	1
183	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. Journal of Clinical Oncology, 2015, 33, 2019-2019.	0.8	1
184	Re-irradiation for relapsed paediatric ependymoma.. Journal of Clinical Oncology, 2016, 34, 10565-10565.	0.8	1
185	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, iii371-iii371.	0.6	1
186	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. Neuro-Oncology, 2021, 23, vi59-vi60.	0.6	1
187	Germline predisposition to glial neoplasms in children and young adults: A narrative review. Glioma (Mumbai, India), 2021, 4, 68.	0.0	1
188	A novel central nervous system embryonal tumor successfully treated with multiâ€modal therapy highlights limitation of methylationâ€based tumor classification. Pediatric Blood and Cancer, 2022, 69, e29520.	0.8	1
189	Liquid biopsy for pediatric brain tumor patients: is it prime time yet?. Neuro-Oncology, 2022, 24, 1773-1775.	0.6	1
190	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. Neuro-Oncology, 2022, 24, i84-i84.	0.6	1
191	Abstract 5224: The PRecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. Cancer Research, 2022, 82, 5224-5224.	0.4	1
192	The neuroprotective effects of anti-cd18 therapy after transient global ischemic brain injury in the mouse. Canadian Journal of Anaesthesia, 2006, 53, 26428-26428.	0.7	0
193	Developmental stage-specific transformation of neural progenitors. Cell Cycle, 2014, 13, 343-344.	1.3	0
194	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. Neuro-Oncology, 2014, 16, iii26-iii27.	0.6	0
195	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. Neuro-Oncology, 2016, 18, iii94.1-iii94.	0.6	0
196	PNR-32UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS - NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES. Neuro-Oncology, 2016, 18, iii13.1-iii13.	0.6	0
197	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i106-i106.	0.6	0
198	ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i36-i36.	0.6	0

#	Article	IF	Citations
199	DIPG-55. TARGETING SENESCENT CELLS WITH ABT-263 ENHANCES CELL DEATH INDUCED BY BMI1 INHIBITION AND IONIZING RADIATION IN DIPG. Neuro-Oncology, 2018, 20, i60-i60.	0.6	0
200	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). Neuro-Oncology, 2018, 20, i79-i79.	0.6	0
201	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology, 2018, 20, i92-i92.	0.6	0
202	MBRS-62. REPRESSIVE CHROMATIN REMODELERS IN SHH-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i141-i141.	0.6	0
203	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. Neuro-Oncology, 2018, 20, i66-i66.	0.6	0
204	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. Neuro-Oncology, 2018, 20, i186-i186.	0.6	0
205	LGG-49. MOLECULAR ALTERATIONS IN PREGNANT ADOLESCENT AND YOUNG ADULT WOMEN WITH GLIOMA. Neuro-Oncology, 2018, 20, i115-i115.	0.6	0
206	EMBR-12. IMPROVED DIAGNOSTIC ALGORITHM FOR DIFFERENTIAL DIAGNOSTICS OF CNS EMBRYONAL TUMORS (FORMER CNS-PNET) BY NEUROPATHOLOGICAL RE-EVALUATION OF 256 CASES AND CROSSVALIDATION BY METHYLATION CLASSIFICATION. Neuro-Oncology, 2018, 20, i71-i71.	0.6	0
207	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i117-i117.	0.6	0
208	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. Neuro-Oncology, 2018, 20, i56-i56.	0.6	0
209	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	0.6	0
210	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN <3 YEARS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i63-i63.	0.6	0
211	MEDU-04. AN OTX2-PAX GENE NETWORK REGULATES GROUP 3 MEDULLOBLASTOMA DIFFERENTIATION AND TUMOR GROWTH. Neuro-Oncology, 2019, 21, ii103-ii104.	0.6	0
212	DIPG-22. GENETIC MODELING IMPLICATES RAS AND MYC AS KEY EPIGENETICALLY ACTIVATED TRANSCRIPTIONAL TARGETS OF H3K27M-DRIVEN CANCER. Neuro-Oncology, 2019, 21, ii73-ii73.	0.6	0
213	DIPG-35. OPEN DIPG INITIATIVE: A PLATFORM FOR ACCELERATING DISCOVERY THROUGH DATA ACCESS, CONSOLIDATION AND HARMONIZATION. Neuro-Oncology, 2019, 21, ii76-ii76.	0.6	0
214	HGG-22. CHARACTERIZING THE ROLE H3.3G34R MUTATION IN PEDIATRIC HIGH GRADE ASTROCYTOMA. Neuro-Oncology, 2019, 21, ii91-ii91.	0.6	0
215	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	0.6	0
216	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2019, 21, ii76-ii77.	0.6	0

#	Article	IF	Citations
217	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology, 2019, 21, ii96-ii97.	0.6	0
218	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. Neuro-Oncology, 2019, 21, ii98-ii98.	0.6	0
219	HGG-18. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. Neuro-Oncology, 2019, 21, ii90-ii90.	0.6	0
220	HGG-19. MOLECULAR ANALYSIS UNCOVERS 3 DISTINCT SUBGROUPS AND MULTIPLE TARGETABLE GENE FUSIONS IN INFANT GLIOMAS. Neuro-Oncology, 2019, 21, ii90-ii91.	0.6	0
221	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	0.6	0
222	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, ii123-ii123.	0.6	0
223	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. Neuro-Oncology, 2020, 22, iii327-iii328.	0.6	0
224	Clinical Neuropathological Conference: Thereâ€™s a Child in All of Us. Canadian Journal of Neurological Sciences, 0, , 1-5.	0.3	0
225	Abstract PO052: Uncovering the evolution of Glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers. , 2021, , .		0
226	HGG-39. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. Neuro-Oncology, 2021, 23, i25-i25.	0.6	0
227	OMRT-8. Precision targeting of cellular pathways with complementary diagnostics. Neuro-Oncology Advances, 2021, 3, ii8-ii8.	0.4	0
228	Imaging of metastatic medulloblastoma in the molecular era.. Journal of Clinical Oncology, 2016, 34, e22003-e22003.	0.8	0
229	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. Journal of Clinical Oncology, 2017, 35, 10503-10503.	0.8	0
230	ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM. Neuro-Oncology, 2020, 22, iii282-iii282.	0.6	0
231	MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY. Neuro-Oncology, 2020, 22, iii416-iii416.	0.6	0
232	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, iii295-iii296.	0.6	0
233	LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS. Neuro-Oncology, 2020, 22, iii368-iii368.	0.6	0
234	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. Neuro-Oncology, 2020, 22, iii369-iii370.	0.6	0

#	Article	IF	Citations
235	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. Neuro-Oncology, 2020, 22, iii327-iii327.	0.6	0
236	LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii373-iii373.	0.6	0
237	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii347-iii348.	0.6	0
238	LGG-50. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF 1,000 PEDIATRIC LOW-GRADE GLIOMAS UNCOVERS NOVEL SUBGROUPS FOR CLINICAL RISK STRATIFICATION. Neuro-Oncology, 2020, 22, iii375-iii376.	0.6	0
239	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. Neuro-Oncology, 2020, 22, iii298-iii299.	0.6	0
240	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. Neuro-Oncology, 2020, 22, iii427-iii427.	0.6	0
241	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	0.6	0
242	EXTH-30. HARNESSING CELLULAR STRESS FOR IMMUNE TARGETING OF DIPGS. Neuro-Oncology, 2021, 23, vi169-vi170.	0.6	0
243	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. Neuro-Oncology, 2021, 23, vi114-vi115.	0.6	0
244	TAMI-29. MULTIFACTORIAL UPREGULATION OF ID1 DRIVES DIPG INVASIVENESS AND IS THERAPEUTICALLY TARGETABLE. Neuro-Oncology, 2020, 22, ii219-ii219.	0.6	0
245	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. Neuro-Oncology, 2020, 22, ii154-ii154.	0.6	0
246	CTNI-24. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. Neuro-Oncology, 2020, 22, ii47-ii47.	0.6	0
247	DDRE-06. CELLULAR STRESS RESPONSE IN DIPG THERAPY. Neuro-Oncology, 2020, 22, ii62-ii62.	0.6	0
248	Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. BMC Pediatrics, 2022, 22, 13.	0.7	0
249	The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review. Glioma (Mumbai, India), 2022, 5, 5.	0.0	0
250	EPCO-16. ONCOHISTONE INTERACTOME PROFILING UNCOVERS MECHANISMS OF CHROMATIN DISRUPTION AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS IN PEDIATRIC HIGH-GRADE GLIOMA. Neuro-Oncology, 2021, 23, vi5-vi5.	0.6	0
251	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. Neuro-Oncology, 2022, 24, i97-i97.	0.6	0
252	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	0.6	0